Press Release Archive

(BUSINESS WIRE)--Pfizer: ($ in millions, except per-share amounts) Third Quarter Year to Date 2007 2006

(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc, today released a landmark independent report researched and written by FSG on the state of international corporate volunteering (ICV) programs. The report details the landscape of this emerging trend among multinationals, the perceived business value of ICV and community impact, and the business

(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Dr. Corey Goodman; and named Dr. Briggs Morrison, who held senior research and development positions at Merck, as its new Head of Clinical Development for the PGRD pipeline. “As the

(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra would be infringed by Apotex’ proposed generic product. The court granted the company’s application for an order preventing Apotex from launching a generic version of Viagra until expiration of Canadian Patent No. 2,163,446 in 2014. The decision is subject to

(BUSINESS WIRE)--Pfizer Inc announced today the election of Suzanne Nora Johnson and James M. Kilts to the Pfizer Board of Directors effective September 27, 2007. Ms. Johnson, 50, retired as Vice Chairman of The Goldman Sachs Group Inc. in January 2007. She had been with the firm for 21 years in roles ranging from the head of health care investment banking to the head of global research and the Chairman of the Global Markets

(BUSINESS WIRE)--Pfizer Inc announced today that the European Commission (EC) has approved Celsentri® (maraviroc). Treatment-experienced HIV patients in the EU can soon benefit from the first CCR5 antagonist and only oral entry inhibitor. Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 virus detectable

(BUSINESS WIRE)--Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes. Grants will be awarded for, but not limited to, research focusing

(BUSINESS WIRE)--Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting. This newly approved CCR5 antagonist – the first new class of

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Senior Vice President, Pfizer Inc., President, Worldwide Pharmaceutical Operations, at the 37th Annual Bank of America Investment Conference on Wednesday, September 19 at 9:00 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on